Fundraising Fox
Unleash Immuno Oncolytics
St. Louis, US · Founded 2015 · Delaware corporation · 2 known investors
Find your way into Unleash Immuno Oncolytics
Sign up to see every warm intro you have to Unleash Immuno Oncolytics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Unleash Immuno Oncolytics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Unleash Immuno Oncolytics is an immuno-oncology company developing armed, conditionally replicating oncolytic viruses that target both tumor cells and the tumor-associated stroma to trigger a systemic anti-cancer immune response. Its lead product uses virally produced cytokines to disrupt tumor architecture and treat cancers, including metastatic disease.
Founders & leadership
Investors · 2
Also in the syndicate · 1
Oncolys BioPharma
Reported raises · per SEC filings
Form D private placements$3M disclosed across 1 round · 2018
▶$3MraisedFeb 2018 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedFeb 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ariel MusleraDirector
- Ricardo Lisandro BrilDirector
- Daniel KatzmanExecutive Officer, Director
- Bolten CharlesDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Unleash Immuno Oncolytics do?
- Unleash Immuno Oncolytics is an immuno-oncology company developing armed, conditionally replicating oncolytic viruses that target both tumor cells and the tumor-associated stroma to trigger a systemic anti-cancer immune response. Its lead product uses virally produced cytokines to disrupt tumor architecture and treat cancers, including metastatic disease.
- Who are Unleash Immuno Oncolytics's investors?
- Unleash Immuno Oncolytics's investors include BioGenerator Ventures.
- How much funding has Unleash Immuno Oncolytics raised?
- Unleash Immuno Oncolytics has disclosed $3M raised across 1 round.
- Where is Unleash Immuno Oncolytics headquartered?
- Unleash Immuno Oncolytics is headquartered in St. Louis, US.